<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Fertil Steril</journal-id><journal-id journal-id-type="iso-abbrev">Int J Fertil Steril</journal-id><journal-id journal-id-type="publisher-id">Royan Institute</journal-id><journal-title-group><journal-title>International Journal of Fertility &#x00026; Sterility</journal-title></journal-title-group><issn pub-type="ppub">2008-076X</issn><issn pub-type="epub">2008-0778</issn><publisher><publisher-name>Royan Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24520498</article-id><article-id pub-id-type="pmc">3901183</article-id><article-id pub-id-type="other">Int-J-Fertil-Steril-7-281</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject><subj-group><subject>Immunology</subject><subject>Gynecology and Female Infertility</subject></subj-group></subj-group></article-categories><title-group><article-title>Possible Role of Autoimmunity in Patients with
Premature Ovarian Insufficiency</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ko&#x00161;ir Poga&#x0010d;nik</surname><given-names>Renata</given-names></name><degrees>M.D</degrees><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Meden Vrtovec</surname><given-names>Helena</given-names></name><degrees>Ph.D</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vizjak</surname><given-names>Alenka</given-names></name><degrees>Ph.D</degrees><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ur&#x00161;ula Levi&#x0010d;nik</surname><given-names>Alenka</given-names></name><degrees>M.D</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Slabe</surname><given-names>Nina</given-names></name><degrees>M.D</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ihan</surname><given-names>Alojz</given-names></name><degrees>Ph.D</degrees><xref ref-type="aff" rid="A3">3</xref></contrib><aff id="A1"><label>1</label>Department of Obstetrics and Gynecology, University Medical Centre Ljubljana, Ljubljana, Slovenia</aff><aff id="A2"><label>2</label>Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia</aff><aff id="A3"><label>3</label>Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana,
Ljubljana, Slovenia</aff></contrib-group><author-notes><corresp id="cor1">
* Corresponding Address:
<addr-line>Department of Obstetrics and Gynecology</addr-line><institution>University Medical Centre Ljubljana</institution><addr-line>&#x00160;lajmerjeva 3</addr-line><addr-line>SI-1000 Ljubljana</addr-line><country>Slovenia</country>
Email: <email>renata.kosir@inbox.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jan-Mar</season><year>2014</year></pub-date><pub-date pub-type="epub"><day>22</day><month>12</month><year>2013</year></pub-date><volume>7</volume><issue>4</issue><fpage>281</fpage><lpage>290</lpage><history><date date-type="received"><day>17</day><month>11</month><year>2012</year></date><date date-type="accepted"><day>7</day><month>4</month><year>2013</year></date></history><permissions><copyright-statement>Any use, distribution, reproduction or abstract of this publication in any medium, with the exception of commercial purposes, is permitted provided the original work is properly cited</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
</license-p></license></permissions><abstract><sec><title>Background:</title><p> To evaluate the involvement of immune abnormality in patients with idiopathic premature ovarian insufficiency (POI). In addition to the known etiology, autoimmune disorders may be a pathologic mechanism for POI. </p></sec><sec><title>Materials and Methods:</title><p> Our study was a prospective controlled trial. Twenty women
with POI, reasons other than autoimmune excluded, were enrolled in this study.
The control group consisted of 17 healthy women. In both groups, family and personal history were taken and the levels of follicle stimulating hormone, luteinizing
hormone, thyroid-stimulating hormone, prolactin, anti-M&#x000fc;llerian hormone, inhibin
B, antithyroglobulin and antithyroid peroxidase antibodies were determined. Antiovarian antibodies and subpopulations of peripheral blood T-lymhocytes were also
determined.</p></sec><sec><title>Results:</title><p> Participants in the study group exhibited hypergonadotropichypogonadism,
while high levels of follicle stimulating hormone and low levels of inhibin B and anti-M&#x000fc;llerian hormone were observed. In 16 (80%) patients, POI was associated in their
personal and familial history with another autoimmune disease. Fifty percent of patients
presented highly elevated antithyroid antibodies. The lymphocyte subset, especially B
cells, was significantly higher (p=0.014), and peripheral regulatory lymphocytes CD25+
high were significantly lower (p=0.015) in the study group than in the control group. Anti-
ovarian antibodies were detected in 20% of patients with POI. </p></sec><sec><title>Conclusion:</title><p> We presume that the presence of anti-ovarian antibodies together with abnormalities of cellular immunity may in some cases potentially represent the involvement of an autoimmune mechanism in idiopathic POI. </p></sec></abstract><kwd-group><kwd>Autoantibody</kwd><kwd>Thyroid Stimulating Antibody</kwd><kwd>Cell Immunity</kwd><kwd>Premature
Ovarian Insufficiency</kwd><kwd>T-Lymphocyte</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>Citation</meta-name><meta-value>Ko&#x00161;ir Poga&#x0010d;nik R, Meden Vrtovec H, Vizjak A, Ur&#x00161;ula Levi&#x0010d;nik A, Slabe N, Ihan A. Possible role of autoim-
munity in patients with premature ovarian insufficiency. Int J Fertil Steril. 2014; 7(4): 281-290.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec><title>Introduction</title><p>Premature ovarian insufficiency (POI) is characterized
by hypergonadotropic amenorrhea due to
cessation of ovarian function before the age of 40
years. The diagnosis is based on amenorrhea before
the age of 40 associated with follicle stimulating
hormone (FSH) levels &#x0003e;40 IU/l, detected on
two occasions at least one month apart (<xref rid="B1" ref-type="bibr">1</xref>). POI
causes female infertility, while is a significant psychosocial
burden and a risk to women&#x02019;s health. It
occurs in 1% of women, of whom 10-28% have
primary and 4-18% secondary amenorrhea (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>).</p><p>Although there are multiple etiologies of POI
(genetic, chromosomal, infectious, and iatrogenic
causes), the etiology cannot be identified in most
patients and this is referred to as idiopathic POI;
up to 30% of idiopathic cases may have an autoimmune
cause (<xref rid="B4" ref-type="bibr">4</xref>). The most convincing evidence
coming from the commonly observed association
of POI with other autoimmune disorders (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>) are
demonstration of anti-ovarian antibodies (AOA,
<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>) and histological findings of ovarian tissue
from affected women. Roughly, one third of POI
patients have AOA and/or antithyroid antibodies
in their serum (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B9" ref-type="bibr">9</xref>). Various organ-specific and
systemic autoimmune diseases cause autoimmune
ovarian insufficiency in up to 30% of women with
POI (<xref rid="B4" ref-type="bibr">4</xref>). According to the literature, 2-10% of POI
cases are known to be associated with adrenal autoimmunity
(<xref rid="B10" ref-type="bibr">10</xref>). One of the first signs that autoimmunity
may be responsible for ovarian function
failure came from the observation that ovarian
failure may precede the onset of Addison&#x02019;s disease
by 8-14 years (<xref rid="B11" ref-type="bibr">11</xref>). Autoimmune Addison&#x02019;s disease
seldom develops in isolation, whereas several
other endocrine glands and organs are generally
affected, leading to an autoimmune polyglandular
syndrome (APGS, <xref rid="B12" ref-type="bibr">12</xref>). Two main forms of APGS
can be clinically discerned, APGS types 1 and 2.
APGS type 1 is characterized by an association of
mucocutaneous candidiasis, hypoparathyroidism
and Addison&#x02019;s disease. In about 60% of cases,
there is also an association with ovarian insufficiency.
Blizzard et al. (<xref rid="B13" ref-type="bibr">13</xref>) and Irvine et al. (<xref rid="B14" ref-type="bibr">14</xref>)
found that POI commonly presents with adrenal
cytoplasmic antibodies, called steroid cell antibodies
(SCA); they react with cytoplasmic antigens of
other steroid-producing cells present in the ovary,
testis and placenta. Alteration of lymphocytes and
their specific subsets, as well as T-cell mediated
injury are likely to play an important role in the
pathogenesis of autoimmune oophoritis. Surface
markers of peripheral blood mononuclear cells
(PBMC) have been shown to be deranged in early
autoimmune phases and to be persisted through
the disease, even after targeted disruption (<xref rid="B15" ref-type="bibr">15</xref>).</p><p>The presence of pathogenic factors might accelerate
the process of apoptosis and atresia of ovarian
follicles during the fetal and post-natal period
(<xref rid="B16" ref-type="bibr">16</xref>). This interpretation is based on the dogma that
the number of ovarian follicles at birth is final and
that there is no possibility of regeneration or renewal
of reserve follicles in adulthood (<xref rid="B17" ref-type="bibr">17</xref>). Experimental
work on animals suggests a possibility
of renewal of the follicle reserve from proliferative
germinal ovarian cells even after birth; verification
of which is being sought in studies on human ovaries
(<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>). It has been shown that undifferentiated
ovarian stem cells differentiate into structures
similar to egg cells under certain laboratory conditions
(<xref rid="B20" ref-type="bibr">20</xref>). We faced two problems: whether to accept
the standard understanding of a final number
of ovarian follicles or to focus on the hypothetic
possibility of renewal of the follicular reserve. The
aim of this study was to evaluate the involvement
of immune abnormality in patients with idiopathic
POI.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><sec><title>Subjects</title><p>
Our study was a prospective randomized controlled
trial. The study group consisted of 20 women
with POI (mean age 31.8 years, range 20-39
years) and no use of medications or oral contraceptives
for at least 4 months prior to the study. The diagnosis
was based on the presence of amenorrhea
before the age of 40, associated with two serum
FSH levels above 40 IU/l at least one month apart.
All women with POI underwent karyotyping and
genetic testing of the fragile X mental retardation
1 (FMR1). Women with infectious or iatrogenic
causes were excluded from the study. The control
group consisted of 17 healthy women volunteers.
Inclusion criteria were a regular menstrual cycle,
age between 18 and 39 years (mean 30.8 years),
and no use of medications or oral contraceptives
for at least 4 months prior to the study. They also
had to be exempt from autoimmune disease or infertility
problems. All women provided a complete
personal and family history, with a stress on possible
immune-mediated, particularly autoimmune
processes (allergy, asthma, diabetes, thyroiditis,
rheumatoid arthritis, andatopiceczema), and all
underwent physical and vaginal ultrasound examinations.</p></sec><sec><title>Hormone and serological analyses</title><p>
Serum levels of luteinizing hormone (LH), FSH,
estradiol (E<sub>2</sub>), prolactin (PRL), inhibin B, thyroid-
stimulating hormone (TSH), anti-M&#x000fc;llerian
hormone (AMH), antithyroglobulin (aTG) and
antithyroid peroxidase antibodies (aTPO) were measured, and immunological investigations at
cellular and humoral levels were performed. The
adrenocorticotropic hormone (ACTH) stimulation
test was performed in the study group, only. The
standard Synacthen stimulation test is clinically
widely used as a sensitive screening method for
symptomatic adrenal insufficiency. Each ampoule
of Synacthen contains 250 &#x003bc;g of the active ingredient,
tetracosactrin (Novartis Pharmaceuticals,
North Ryde NSW, Australia). Thirty minutes after
250 &#x003bc;g Synacthen I.M. (Alliance Pharmaceutical
Wiltshire, UK), blood cortisol was measured by
electro-chemiluminescence immunoassay. A normal
cortisol response to Synacthen was defined
as a post-stimulation peak cortisol value of &#x0003e;500
nmol/l at 30 minutes.</p><p>Serum AMH in peripheral blood was determined
by a Personal Lab analyser using the
enzyme linked immunosorbent assay (ELISA)
method with Beckman Coulter reagent. The
normal range of AMH levels is 0.7-3.5 mg/l.
Values below 0.3 mg/l indicate a reduced ovarian
reserve. Hormones were determined on a LIAISON
analyser by quantitative direct competitive
chemiluminescence immunoassays (CLIA).
Each test is a modified two-step process, in
which the specific antibodies of a certain hormone
bind to magnetic cells. Normal ranges for
the follicular phase of the cycle are as follows:
FSH: 3.5-9.2 IU/l; LH: 1.1-11.6 IU/l; LH around
ovulation: 17-77 IU/l; PRL: 6.2-23.5 &#x003bc;g/l; E<sub>2</sub>:
on day 3 up to 310 pmol/L (0.31 nmol/L); E<sub>2</sub>
postmenopause: 0-110 pmol/L (0-0.11 nmol/l);
and TSH: 0.3-3.6 mE/l. Serum Inhibin-B cut-off
level on day 3 was 45 pg/mL. Serum aTG and
aTPO concentrations measured by immunoassay
using direct chemiluminometric technology
on an ADVIA CENTAUR analyser (Siemens
Medical Solutions Diagnostics, Tarrytown,
USA). The normal range for serum aTG and
aTPO is &#x0003c;60 KE/l. Detection of AOA was by
indirect immunofluorescence (IIF) on cryosections
of normal human ovarian tissue.</p><p>Non-human primate ovaries for the detection
of AOA are not commercially available, while
normal human ovarian tissue is available at
the Institute of Pathology, Ljubljana, Slovenia,
when ovaries are removed due to various pathological
processes, particularly tumors, and are
sent for pathohistological examination. Ovarian
tissue was incubated with patient serum diluted
1:10. The second incubation was with fluorescein
isothiocyanate-labelled anti-human IgG antibody
(Dakopatts, Copenhagen, Denmark). Positive reactions
were semi-quantitatively evaluated (on a
scale of 1&#x02013; 4+). Negative control omitting the patient&#x02019;s
serum was regularly included (<xref rid="B21" ref-type="bibr">21</xref>). At the
cellular level fresh PBMC were studied by flow
cytometry (Becton Dickinson FACS, NJ, USA),
and percentages of the following blood lymphocyte
populations were determined: T cells (CD3+),
helper T cells (CD4+), cytotoxic T cells (CD8+),
natural killer cells (CD56+CD16+), regulatory T
cells (CD25<sup>+high</sup>) and B cells (CD19+) (<xref rid="B22" ref-type="bibr">22</xref>). Immunofluorescence
labelling was performed by incubating
PBMCs with monoclonal antibodies to
CD3, CD4, CD8, CD25, CD56/16 and CD45. A
differential blood count with a standard laboratory
procedure was taken to obtain concentrations of
individual lymphocyte subtypes.</p></sec><sec><title>Statistical analysis</title><p>
Normal data distribution was tested with the
Kolmogorov-Smirnov test. Where variables were
normally distributed, we used the Pearson&#x02019;s chisquare
test. If variables were not normally distributed,
we used a nonparametric Mann-Whitney
test. Statistical analysis was done using Statistical
Package for the Social Sciences, version 18 (SPSS
Inc., Chicago, IL, USA). The results were considered
statistically significant at p&#x0003c;0.05.</p></sec><sec><title>Ethical considerations</title><p>
The study protocol was approved by the National
Ethics Committee, and all patients gave written
informed consent.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>General clinical and biological parameters</title><p>
The subjects were comparable with controls by
age. One patient presenting a mosaic 45X0/46XX
was excluded from the final analysis. Other patients
had a 46XX karyotype. Anamnestic data of
patients showed that four had had mumps during
their childhood; they were thus excluded from the
final analysis. Table 1 shows the clinical and endocrine
characteristics of patients and of healthy
women. All endocrine parameters in controls were
within the normal range (<xref ref-type="table" rid="T1">Table 1</xref>).</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p> Hormone and ovarian peptide levels in patients and in healthy controls</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="3" rowspan="1"><hr/></th></tr><tr><th rowspan="1" colspan="1">Mean value+/- SD</th><th rowspan="1" colspan="1">Study group (n=20)</th><th rowspan="1" colspan="1">Control group (n=17)</th></tr><tr><th colspan="3" rowspan="1"><hr/></th></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FSH (IU/L)</bold></td><td rowspan="1" colspan="1">88.04 +/- 47.93</td><td rowspan="1" colspan="1">6.25 +/- 2,77</td></tr><tr><td rowspan="1" colspan="1"><bold>LH (IU/L)</bold></td><td rowspan="1" colspan="1">37.85 +/- 18.71</td><td rowspan="1" colspan="1">11.64 +/- 31.1</td></tr><tr><td rowspan="1" colspan="1"><bold>E<sub>2</sub> (pmol/L)</bold></td><td rowspan="1" colspan="1">180 +/- 200 (0.18 +/- 0.2nmol/L)</td><td rowspan="1" colspan="1">210+/- 130 (0.21 +/- 0.13nmol/L)</td></tr><tr><td rowspan="1" colspan="1"><bold>PRL (&#x003bc;g/L)</bold></td><td rowspan="1" colspan="1">11.14 +/- 6.42</td><td rowspan="1" colspan="1">8.74 +/- 5.51</td></tr><tr><td rowspan="1" colspan="1"><bold>Inhibin B (pg/ml)</bold></td><td rowspan="1" colspan="1">13.36 +/- 10.66</td><td rowspan="1" colspan="1">32.63 +/- 24.05</td></tr><tr><td rowspan="1" colspan="1"><bold>AMH (mg/L)</bold></td><td rowspan="1" colspan="1">0.36 +/- 0.37</td><td rowspan="1" colspan="1">3.54 +/- 1.58</td></tr><tr><th colspan="3" rowspan="1"><hr/></th></tr></tbody></table><table-wrap-foot><fn><p>POI; Premature ovarian insufficiency, FSH; Follicle stimulating hormone, LH; Luteinizing hormone, E<sub>2</sub>; Estradiol, PRL; Prolactine and AMH; Anti-M&#x000fc;llerian hormone.
</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Prevalence of autoimmune diseases and associated
autoimmune abnormalities</title><p>We collected targeted history information on
personal and familial autoimmune disorders (<xref ref-type="table" rid="T2">Table
2</xref>). Sixteen patients (80%) had an associated
autoimmune disease in their personal and/or familial
history. Four women (20%) with POI had
first grade relatives with ovarian insufficiency
before the age of 40. Thyroid disorders were the
most common (15%) of the autoimmune diseases
associated with POI in personal histories. Before
entering the study, three patients had been treated
for autoimmune thyroid dysfunction (Hashimoto
thyroiditis). In the study group, 55% of women
had autoimmune disease in the family history; the
most frequent autoimmune disorder was diabetes
type I. The overall personal and familial incidence
of autoimmune diseases was lower in the control
group. In the study group, 50% of women had
aTG. One healthy woman had evidence of autoimmune
thyroid dysfunction, manifested by an elevated
aTG serum level, and was excluded from
the final analysis (Tables <xref ref-type="table" rid="T2">2</xref>,<xref ref-type="table" rid="T3">3</xref>).</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p> Personal and family history on autoimmune diseases in patients and healthy controls</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="5" rowspan="1"><hr/></th></tr><tr><th rowspan="1" colspan="1"/><th colspan="2" rowspan="1">Study group (n=20)</th><th colspan="2" rowspan="1">Control group (n=17)</th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Family history</th><th rowspan="1" colspan="1">Personal history</th><th rowspan="1" colspan="1">Family history</th><th rowspan="1" colspan="1">Personal history</th></tr><tr><th colspan="5" rowspan="1"><hr/></th></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Diabetes type I</bold></td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><bold>Psoriasis</bold></td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1"><bold>Rheumatism</bold></td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><bold>Thyroid disease</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1"><bold>Vitiligo</bold></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><bold>POI</bold></td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><bold>Atopic dermatitis</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td></tr><tr><th colspan="5" rowspan="1"><hr/></th></tr></tbody></table><table-wrap-foot><fn><p>POI ; Premature ovarian insufficiency.
</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p> Associated autoimmune abnormalities (some participants showed more than one condition)</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="3" rowspan="1"><hr/></th></tr><tr><th rowspan="1" colspan="1">Associated autoimmune findings</th><th rowspan="1" colspan="1">Study group</th><th rowspan="1" colspan="1">Control group</th></tr><tr><th colspan="3" rowspan="1"><hr/></th></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Anti-thyroglobulin antibody (aTG)</bold></td><td rowspan="1" colspan="1">10 (50%)</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1"><bold>Positive ACTH test</bold></td><td rowspan="1" colspan="1">5 (25%)</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1"><bold>Anti-ovarian antibodies (AOA)</bold></td><td rowspan="1" colspan="1">4 (20%)</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1"><bold>Personal history of autoimmune disease</bold></td><td rowspan="1" colspan="1">6 (30%)</td><td rowspan="1" colspan="1">2 (11.1%)</td></tr><tr><td rowspan="1" colspan="1"><bold>Family history of autoimmune disease</bold></td><td rowspan="1" colspan="1">11 (55%)</td><td rowspan="1" colspan="1">4 (22.2%)</td></tr><tr><td rowspan="1" colspan="1"><bold>POI in family members</bold></td><td rowspan="1" colspan="1">4 (20%)</td><td rowspan="1" colspan="1">0</td></tr><tr><th colspan="3" rowspan="1"><hr/></th></tr></tbody></table><table-wrap-foot><fn><p>POI; premature ovarian insufficiency.
</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Anti-ovarian antibodies</title><p>
Analysis of AOA in serum was performed for all
patients (<xref ref-type="fig" rid="F1">Fig 1</xref>). AOA were detected in 4 (20%)
patients, and in 3 patients, we found an associated
autoimmune disease; Hashimoto thyroiditis. There
was a clear positive immune fluorescent reaction of
AOA in the serum of one woman who had mumps
during her childhood, and she was excluded from
the analysis. AOA were not detected in any of the
controls (<xref ref-type="table" rid="T3">Table 3</xref>).</p><fig id="F1" orientation="portrait" position="float"><label>Fig 1</label><caption><p>Prevalence of serum anti-ovarian antibodies (AOA)
in patients.</p></caption><graphic xlink:href="Int-J-Fertil-Steril-7-281-g01"/></fig></sec><sec><title>Lymphocyte subtypes</title><p>
Cellular autoimmune reaction occurring due to
a changed T cell function was analysed as a potential
cause of POI. Cell abnormalities were more
frequent in women with POI than in healthy women
(<xref ref-type="table" rid="T4">Table 4</xref>).</p><p>Peripheral T cell count is expressed as a percentage
of various cell surface markers. In patients
with POI, peripheral regulatory T lymphocytes
(CD25<sup>+high</sup>, p=0.015) were low and peripheral
blood B cells (CD19+) were high (p=0.014); T
lymphocyte parameters were normal in the control
group.</p><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><p> Prevalence (in %) of analysed peripheral blood lymphocyte samples for various cell surface markers in patients and in controls</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="4" rowspan="1"><hr/></th></tr><tr><th rowspan="1" colspan="1">Various cell surface markers</th><th rowspan="1" colspan="1">Study group (%)</th><th rowspan="1" colspan="1">Control group (%)</th><th rowspan="1" colspan="1">P value</th></tr><tr><th colspan="4" rowspan="1"><hr/></th></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CD3<sup>+</sup></bold></td><td rowspan="1" colspan="1">73.25</td><td rowspan="1" colspan="1">74.53</td><td rowspan="1" colspan="1">0.578</td></tr><tr><td rowspan="1" colspan="1"><bold>CD19<sup>+</sup></bold></td><td rowspan="1" colspan="1">11.90</td><td rowspan="1" colspan="1">9.41</td><td rowspan="1" colspan="1">0.014</td></tr><tr><td rowspan="1" colspan="1"><bold>CD4<sup>+</sup></bold></td><td rowspan="1" colspan="1">47.45</td><td rowspan="1" colspan="1">45.82</td><td rowspan="1" colspan="1">0.450</td></tr><tr><td rowspan="1" colspan="1"><bold>CD8<sup>+</sup></bold></td><td rowspan="1" colspan="1">25.85</td><td rowspan="1" colspan="1">28.53</td><td rowspan="1" colspan="1">0.229</td></tr><tr><td rowspan="1" colspan="1"><bold>CD25<sup>+</sup><sup>h</sup><sup>i</sup><sup>g</sup><sup>h</sup></bold></td><td rowspan="1" colspan="1">1.60</td><td rowspan="1" colspan="1">2.85</td><td rowspan="1" colspan="1">0.015</td></tr><tr><td rowspan="1" colspan="1"><bold>CD56<sup>+</sup>CD16<sup>+</sup></bold></td><td rowspan="1" colspan="1">14.20</td><td rowspan="1" colspan="1">16.23</td><td rowspan="1" colspan="1">0.366</td></tr><tr><th colspan="4" rowspan="1"><hr/></th></tr></tbody></table><table-wrap-foot><fn><p>Markers for peripheral blood lymphocytes: T lymphocytes (CD3+), helper T lymphocytes (CD4+), cytotoxic T lymphocytes (CD8+), natural killer cells (CD56+CD16+), regulatory T lymphocytes (CD25<sup>+high</sup>) and B cells (CD19+).
</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>To present POI as a possible autoimmune abnormality,
we focused on three potentially interconnected
factors: personal and familial history
of autoimmune disorders, peripheral blood T-lymphocytes
levels and presence of AOA.</p><p>We performed a targeted history of personal and
familial autoimmune disorders and found associated
autoimmune disorders in our patients. Thyroid
disorders were common in personal histories and
diabetes type 1 in familial histories, confirming the
findings of previous studies (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B15" ref-type="bibr">15</xref>). One of the
reasons for suspecting an autoimmune etiology
of POI is its frequent association with nearly all
organ-specific autoimmune diseases (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B3" ref-type="bibr">3</xref>). Autoimmune
diseases are significantly more frequent in
young women than in men. This phenomenon may
be explained by the effect of sex steroids on the
components of the cellular immune system, which
might contribute to the development and progression
of autoimmune POI (<xref rid="B23" ref-type="bibr">23</xref>).</p><p>Hoek et al. (<xref rid="B24" ref-type="bibr">24</xref>) found that 60% of patients with
secondary amenorrhea and Addison&#x02019;s disease have
a detectable SCA serum titre. These antibodies are
shown by 60-80% of patients with APGS type I. In
25% of our patients, the Synacthen test revealed
an abnormal cortisol response. We interpreted this
as the possibility that patients could be positive for
SCA, but had a normal cortisol response. Patients
with this disorder have an insidious onset; to confirm
subclinical autoimmune adrenal insufficiency,
measurement of adrenal antibodies might be a
more effective screening method (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>).</p><p>Thyroid disorders and the presence of antithyroid
antibodies are often mentioned in association
with POI. Thyroid disorders are the most common
of the autoimmune diseases associated with
POI, found in 12-39% of women with POI (<xref rid="B27" ref-type="bibr">27</xref>-
<xref rid="B29" ref-type="bibr">29</xref>). Thyroid disorders are often associated with
endometriosis and polycystic ovary syndrome,
two conditions often resulting in infertility (<xref rid="B2" ref-type="bibr">2</xref>). We
found a greater involvement of aTG and aTPO in
the study than in the control group, and the explanation
being that ovarian failure may have been
present in the latent period of thyroid disease. We
found a strong correlation between autoimmune
thyroid disease and autoimmune POI; 50% of patients
tested positive for aTG. We concluded that
not all patients with positive aTG necessarily have
a clinically expressed thyroid disorder and the
disease can have an insidious onset. Furthermore,
greater involvement of other immune-mediated
diseases, particularly auto immune disorders, such
as allergy, psoriasis, atopic dermatitis and vitiligo
in the study group suggests an autoimmune cause
of POI, consistent also with the findings in the literature
(<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>).</p><p>Genetic predisposition is known to be one of the
primary causes of autoimmunity and it is generally
observed that patients with autoimmune diseases
have several types of antibodies, as also confirmed
in our study. We found AOA in 20% of patients;
these results are consistent with other studies (<xref rid="B9" ref-type="bibr">9</xref>,
<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B32" ref-type="bibr">32</xref>-<xref rid="B35" ref-type="bibr">35</xref>). The prevalence of AOA in women with
POI, studied with IF on ovary tissue, varies greatly
from 2 to 70%, which supports their role as a
marker of an immune dysfunction process against
ovaries. There could be several reasons for the differences
among study results, including the diverse
origin of tissue sections, which include human and
non-human primate ovaries, as well as different
study inclusion criteria. Many studies have shown
that the presence of serum AOA does not correlate
with the clinical manifestation of POI. Despite
these antibodies being present, their pathogenetic
role is highly questionable (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>). AOA may occur
several years before the occurrence of clinical
symptoms, as detected in 33-61% of women
with unexplained infertility; a situation that may
indicate early stages of autoimmune ovarian insufficiency
(<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>). For most autoimmune diseases,
screening for specific antibodies is probably the
best way of evaluating immunological involvement.
Many ovarian structures are potential targets
for autoimmune events with POI. In addition
to AOA, SCA, aTG and aTPO, antibodies to several
potential ovarian antigens have been proposed
as markers of ovarian autoimmunity, which could
potentially mediate autoimmune damage in POI.
Betterle et al. (<xref rid="B40" ref-type="bibr">40</xref>) found antibodies against steroid
genetic enzymes in some cases with anti-adrenal
autoimmunity. Antibodies against gonadotropin
receptors and gonadotropins have also been found
in patients with POI, but they are still the subject
of research. The general opinion is that more research
is needed (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B42" ref-type="bibr">42</xref>). Although some studies
have managed to identify autoantibodies against
zona pellucida, corpus luteum and ovarian cells,
these findings have no real correlation with the
clinical picture (<xref rid="B43" ref-type="bibr">43</xref>-<xref rid="B45" ref-type="bibr">45</xref>). In our preliminary study, AOA were determined semi-quantitatively by the
IIF method. IIF is a basic method and widely used
for determining auto antibodies, while more specific
tests enabling detection of AOA for specific
antigen targets are not available in our laboratory.</p><p>Infertile women with AOA also have a decreased
response to gonadotropin stimulation and reduced
pregnancy rate after treatment (<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B47" ref-type="bibr">47</xref>). In 2002,
it was found that low-responders to gonadotropins
with AOA are younger than low-responders without
AOA (<xref rid="B48" ref-type="bibr">48</xref>). Detection of autoimmune processes
that affect the ovarian response should thus be included
in the diagnostic workup before any infertility
treatment, particularly in women with low or
no response to gonadotropins (<xref rid="B34" ref-type="bibr">34</xref>). Determination
of AOA, as a specific test, is important in the diagnosis
of diseases with an autoimmune etiology, but
it should not be the only reliable diagnostic tool
for optimal selection of patients who may benefit
from immune modulatory therapy that could, at
least temporarily, re-establish their ovarian function
and fertility.</p><p>Abnormalities of cellular immunity of T lymphocytes,
macrophages and dendritic cells play
an important role in autoimmune events. Some of
these abnormalities have been seen in women with
POI, confirming the potential existence of an autoimmune
mechanism of the disease. Mignot et al.
(<xref rid="B49" ref-type="bibr">49</xref>) found that the absolute number and percentage
of peripheral blood T lymphocytes, especially
CD4+ T cells, are increased in patients with POI.
Moreover, Miyake et al. (<xref rid="B50" ref-type="bibr">50</xref>) found that patients
with POI have low levels of CD8+/CD57+ Tcells
(cytotoxic T lymphocytes) and an increased ratio
of CD4+ to CD8+ cells, which may reflect cell cytotoxic
cell migration from blood to inflamed tissue.
Multiple animal studies have suggested that the basis
of POI is a cell-mediated autoimmune reaction
caused by an alteration in T cell regulation (<xref rid="B18" ref-type="bibr">18</xref>).
CD4+ T cells with constantly expressed &#x003b1; chain
(CD25) receptor for IL-2 of were the first detected
mediators of inhibition of autoimmune diseases in
mice alteration of suppressor T cell subsets and T
cell abnormalities are likely to play an important
role in the pathogenesis of autoimmune diseases
(<xref rid="B51" ref-type="bibr">51</xref>). Regulatory CD4+25+ T cells show a potent
immunosuppressive function in vitro and in vivo,
and contribute to immunologic self-tolerance by
suppressing potentially auto-reactive CD4+ T cells.
There is known to be a number of immunological
mechanisms associated with the failure of immune
tolerance and the development of autoimmunity.
Although studying regulatory T cells in human
autoimmune diseases is difficult, and at times,
findings have been contradictory, the data suggest
that defects in CD4+ CD25+ regulatory T cells
mediated suppression (<xref rid="B52" ref-type="bibr">52</xref>) are a major subset of
immune cells responsible for peripheral immune
self-tolerance.</p><p>In agreement with studies in patients with systemic
lupus erythematosus, multiple sclerosis,
rheumatoid arthritis and autoimmune vasculitis,
we confirmed a reduced number of CD4+CD25<sup>+high</sup>
T cells in the peripheral blood of our patients.
High expressions of CD25 and CD4 surface markers
have classically been used for identification of
regulatory T cells. This may be problematic since
CD25 is also expressed on antigen-responding
activated non-regulatory T cells. The additional
measurement of cellular expression of Foxp3 protein
allowed a more specific analysis of Treg cells
(CD4+CD25+Foxp3+ cells). However, Foxp3 is also
transiently expressed in activated human effector
T cells, thus complicating a correct Treg analysis.
The large majority of Foxp3-expressing regulatory
T cells express high levels of the interleukin-2 receptor
alpha chain (CD25). Since there are no cell
surface markers that are uniquely and specifically
expressed on all Foxp3-expressing regulatory T
cells, the measurement of CD4+CD25<sup>+high</sup> T cells
is still in use in clinical studies of peripheral blood
lymphocytes.</p><p>We interpreted the reduced number of
CD4+CD25<sup>+high</sup> T cells as a possible mechanism
contributing to the formation of an autoimmune
response in association with the presence of AOA
and aTG. We also found an increased number of
B cells in peripheral blood. A similar picture has
been observed with other autoimmune endocrinopathies;
therefore, we interpreted the elevated
B cell count as activation of the humoral immune
system, crucial for autoantibody production. Some
authors, though, have tried estrogen substitution in
women with POI without any effect on peripheral
B cell count (<xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B54" ref-type="bibr">54</xref>).</p><p>The hormones inhibin B, FSH and AMH have
been proposed as potential markers for determining
the functional ovarian reserve (<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B56" ref-type="bibr">56</xref>). In
young ovulatory women, measurement of AMH at
3-year intervals has shown that the AMH serum level decreases significantly over time, whereas
other markers associated with ovarian aging, such
as FSH, inhibin B and antral follicle count (AFC),
do not change during this time period. Since it decreases
at a time when concentrations of FSH and
inhibin B are still normal, AMH has been proposed
as the best indicator of ovarian reserve and as a
marker of ovarian aging (<xref rid="B55" ref-type="bibr">55</xref>-<xref rid="B59" ref-type="bibr">59</xref>). In contrast, AMH
is almost undetectable in women with POI (<xref rid="B60" ref-type="bibr">60</xref>),
which our study also confirmed. In our group of
patients, there was a small AFC or these structures
were no longer seen on ultrasound, which agrees
with the data in the literature (<xref rid="B61" ref-type="bibr">61</xref>).</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Clinical and biological characteristics of women
without known causes of disease suggest a possibility
of autoimmune pathogenesis. In some patients,
a combination of various autoimmune processes
has been found. The presence of AOA and
anti-thyroid antibodies, together with abnormalities
of cellular immunity, potentially represent an
autoimmune mechanism of POI. There is thus an
increasing need to find a reliable and simple diagnostic
procedure to determine the true prevalence
of autoimmune ovarian disease. In women with
POI, more attention should be paid to evaluation
of associated autoimmune disorders.</p></sec></body><back><ack><p>We declare that we had no financial support from
any pharmaceutical or other commercial company.
The study was financed from research funds from
the University Medical Centre Ljubljana, Slovenia,
project number: 20100434. There is no conflict of
interest in this study.</p></ack><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conway</surname><given-names>GS</given-names></name></person-group><article-title>Premature ovarian failure</article-title><source>Br Med Bull</source><year>2000</year><volume>56</volume><issue>3</issue><fpage>643</fpage><lpage>649</lpage><pub-id pub-id-type="pmid">11255551</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goswami</surname><given-names>D</given-names></name><name><surname>Conway</surname><given-names>GS</given-names></name></person-group><article-title>Premature ovarian failure</article-title><source>Horm Res</source><year>2007</year><volume>68</volume><issue>4</issue><fpage>196</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">17495481</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anasti</surname><given-names>JN</given-names></name></person-group><article-title>Premature ovarian failure: an update</article-title><source>Fertil Steril</source><year>1998</year><volume>70</volume><issue>1</issue><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">9660412</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conway</surname><given-names>GS</given-names></name><name><surname>Kaltsas</surname><given-names>G</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Davies</surname><given-names>MC</given-names></name><name><surname>Jacobs</surname><given-names>HS</given-names></name></person-group><article-title>Characterisation of idiopathic premature ovarian failure</article-title><source>Fertil Steril</source><year>1996</year><volume>65</volume><issue>2</issue><fpage>337</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">8566258</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Husebye</surname><given-names>ES</given-names></name><name><surname>L&#x000f8;v&#x000e5;s</surname><given-names>K</given-names></name></person-group><article-title>Immunology of Addison&#x02019;s disease and premature ovarian failure</article-title><source>Endocrinol Metab Clin North Am</source><year>2009</year><volume>38</volume><issue>2</issue><fpage>389</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">19328418</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poppe</surname><given-names>K</given-names></name><name><surname>Velkeniers</surname><given-names>B</given-names></name></person-group><article-title>Female infertility and the thyroid</article-title><source>Best Pract Res Clin Endocrinol Metab</source><year>2004</year><volume>18</volume><issue>2</issue><fpage>153</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">15157833</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edassery</surname><given-names>SL</given-names></name><name><surname>Shatavi</surname><given-names>SV</given-names></name><name><surname>Kunkel</surname><given-names>JP</given-names></name><name><surname>Hauer</surname><given-names>C</given-names></name><name><surname>Brucker</surname><given-names>C</given-names></name><name><surname>Penumatsa</surname><given-names>K</given-names></name><etal/></person-group><article-title>Autoantigens in ovarian autoimmunity associated with unexplained infertility and premature ovarian failure</article-title><source>Fertil Steril</source><year>2010</year><volume>94</volume><issue>7</issue><fpage>2636</fpage><lpage>2641</lpage><pub-id pub-id-type="pmid">20522323</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welt</surname><given-names>CK</given-names></name></person-group><article-title>Autoimmune oophoritis in the adolescent</article-title><source>Ann NY Acad Sci</source><year>2008</year><volume>1135</volume><fpage>118</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">18574216</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashrafi</surname><given-names>M</given-names></name><name><surname>Fallahian</surname><given-names>M</given-names></name><name><surname>Eshrati</surname><given-names>B</given-names></name><name><surname>Salman Yazdi</surname><given-names>R</given-names></name></person-group><article-title>The presence of anti thyroid and anti ovarian auto-antibodies in familial POF</article-title><source>Int J Fertil Steril</source><year>2008</year><volume>1</volume><issue>4</issue><fpage>171</fpage><lpage>174</lpage></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irvine</surname><given-names>WJ</given-names></name><name><surname>Barnes</surname><given-names>EW</given-names></name></person-group><article-title>Addison&#x02019;s disease, ovarian failure and hypoparathyroidism</article-title><source>Clin Endocrinol Metab</source><year>1975</year><volume>4</volume><issue>2</issue><fpage>379</fpage><lpage>434</lpage></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turkington</surname><given-names>RW</given-names></name><name><surname>Lebovitz</surname><given-names>HE</given-names></name></person-group><article-title>Extra-adrenal endocrine deficiencies in Addison&#x02019;s disease</article-title><source>Am J Med</source><year>1967</year><volume>43</volume><issue>4</issue><fpage>499</fpage><lpage>507</lpage><pub-id pub-id-type="pmid">4168683</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Muir</surname><given-names>A</given-names></name><name><surname>Schatz</surname><given-names>DA</given-names></name><name><surname>MacLaren</surname><given-names>NK</given-names></name></person-group><chapter-title>Autoimmune polyglandular
syndrome</chapter-title><person-group person-group-type="editor"><name><surname>de Groot</surname><given-names>LS</given-names></name></person-group><source>Endocrinology</source><edition>3rd ed</edition><publisher-loc>Philadelphia</publisher-loc><publisher-name>WB Saunders</publisher-name><year>1995</year><fpage>3013</fpage><lpage>3024</lpage></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blizzard</surname><given-names>RM</given-names></name><name><surname>Chee</surname><given-names>D</given-names></name><name><surname>Davies</surname><given-names>W</given-names></name></person-group><article-title>The incidence of adrenal and other antibodies in sera of patients with idiopathic adrenal insufficiency (Addison&#x02019;s disease)</article-title><source>Clin Exp Immunol</source><year>1967</year><volume>2</volume><issue>1</issue><fpage>19</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">6030795</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irvine</surname><given-names>WJ</given-names></name><name><surname>Chan</surname><given-names>MM</given-names></name><name><surname>Scarth</surname><given-names>L</given-names></name><name><surname>Kolb</surname><given-names>FO</given-names></name><name><surname>Hartog</surname><given-names>M</given-names></name><name><surname>Bayliss</surname><given-names>RI</given-names></name><etal/></person-group><article-title>Immunological aspects of premature ovarian failure associated with idiopathic Addison&#x02019;s disease</article-title><source>Lancet</source><year>1968</year><volume>2</volume><issue>7574</issue><fpage>883</fpage><lpage>887</lpage><pub-id pub-id-type="pmid">4176147</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forges</surname><given-names>T</given-names></name><name><surname>Monnier-Barbarino</surname><given-names>P</given-names></name><name><surname>Faure</surname><given-names>GC</given-names></name><name><surname>Bene</surname><given-names>MC</given-names></name></person-group><article-title>Autoimmunity and antigenic targets in ovarian pathology</article-title><source>Hum Reprod Update</source><year>2004</year><volume>10</volume><issue>2</issue><fpage>163</fpage><lpage>175</lpage><pub-id pub-id-type="pmid">15073145</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morita</surname><given-names>Y</given-names></name><name><surname>Tilly</surname><given-names>JL</given-names></name></person-group><article-title>Oocyte apoptosis: like sand through an hourglass</article-title><source>Dev Biol</source><year>1999</year><volume>213</volume><issue>1</issue><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">10452843</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuckerman</surname><given-names>S</given-names></name></person-group><article-title>The number of oocytes in the mature ovary</article-title><source>Recent Prog Horm Res</source><year>1951</year><volume>6</volume><issue>1</issue><fpage>63</fpage><lpage>108</lpage></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byskof</surname><given-names>AG</given-names></name><name><surname>Faddy</surname><given-names>MJ</given-names></name><name><surname>Lemmen</surname><given-names>JG</given-names></name><name><surname>Andersen</surname><given-names>CY</given-names></name></person-group><article-title>Eggs forever?</article-title><source>Differentiation</source><year>2005</year><volume>73</volume><issue>9-10</issue><fpage>438</fpage><lpage>446</lpage><pub-id pub-id-type="pmid">16351687</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Lyu</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Albertini</surname><given-names>DF</given-names></name><name><surname>Keefe</surname><given-names>DL</given-names></name><etal/></person-group><article-title>Germline stem cells and neo-oogenesis in the adult human ovary</article-title><source>Dev Biol</source><year>2007</year><volume>306</volume><issue>1</issue><fpage>112</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">17428461</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bukovsky</surname><given-names>A</given-names></name><name><surname>Virant-Klun</surname><given-names>I</given-names></name><name><surname>Svetlikova</surname><given-names>M</given-names></name><name><surname>Willson</surname><given-names>I</given-names></name></person-group><article-title>Ovarian germ cells</article-title><source>Methods Enyzmol</source><year>2006</year><volume>419</volume><fpage>208</fpage><lpage>258</lpage></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damewood</surname><given-names>MD</given-names></name><name><surname>Zacur</surname><given-names>HA</given-names></name><name><surname>Hoffman</surname><given-names>GJ</given-names></name><name><surname>Rock</surname><given-names>JA</given-names></name></person-group><article-title>Circulating antiovarian antibodies in premature ovarian failure</article-title><source>Obstet Gynecol</source><year>1986</year><volume>68</volume><issue>6</issue><fpage>850</fpage><lpage>854</lpage><pub-id pub-id-type="pmid">3537879</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groselj-Grenc</surname><given-names>M</given-names></name><name><surname>Ihan</surname><given-names>A</given-names></name><name><surname>Derganc</surname><given-names>M</given-names></name></person-group><article-title>Neutrophil and monocyte CD64 and CD163 expression in critically ill neonates and children with sepsis: comparison of fluorescence intensities and calculated indexes</article-title><source>Mediators Inflamm</source><year>2008</year><volume>2008</volume><fpage>202646</fpage><lpage>202646</lpage><pub-id pub-id-type="pmid">18604302</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lahita</surname><given-names>RG</given-names></name></person-group><article-title>Predisposing factors to autoimmune disease</article-title><source>Int J Fertil Womens Med</source><year>1997</year><volume>42</volume><issue>2</issue><fpage>115</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">9160222</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoek</surname><given-names>A</given-names></name><name><surname>Schoemaker</surname><given-names>J</given-names></name><name><surname>Drexhage</surname><given-names>HA</given-names></name></person-group><article-title>Premature ovarian failure and ovarian autoimmunity</article-title><source>Endocr Rev</source><year>1997</year><volume>18</volume><issue>1</issue><fpage>107</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">9034788</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakalov</surname><given-names>VK</given-names></name><name><surname>Vanderhoof</surname><given-names>VH</given-names></name><name><surname>Bondy</surname><given-names>CA</given-names></name><name><surname>Nelson</surname><given-names>LM</given-names></name></person-group><article-title>Adrenal autoantibodies detected asymptomatic autoimmune adrenal insufficiency in young women with spontaneous premature ovarian failure</article-title><source>Hum Reprod</source><year>2002</year><volume>17</volume><issue>8</issue><fpage>2096</fpage><lpage>2100</lpage><pub-id pub-id-type="pmid">12151443</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brozzetti</surname><given-names>A</given-names></name><name><surname>Marzotti</surname><given-names>S</given-names></name><name><surname>La Torre</surname><given-names>D</given-names></name><name><surname>Bacosi</surname><given-names>ML</given-names></name><name><surname>Morelli</surname><given-names>S</given-names></name><name><surname>Bini</surname><given-names>V</given-names></name><etal/></person-group><article-title>Autoantibody responses in autoimmune ovarian insufficiency and in Addison&#x02019;s disease are IgG1 dominated and suggest a predominant, but not exclusive, Th1 type of response</article-title><source>Eur J Endocrinol</source><year>2010</year><volume>163</volume><issue>2</issue><fpage>309</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">20498138</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dragojevic-Dikic</surname><given-names>S</given-names></name><name><surname>Marisavljevic</surname><given-names>D</given-names></name><name><surname>Mitrovic</surname><given-names>A</given-names></name><name><surname>Dikic</surname><given-names>S</given-names></name><name><surname>Jovanovic</surname><given-names>T</given-names></name><name><surname>Jankovic-Raznatovic</surname><given-names>S</given-names></name></person-group><article-title>An immunological insight into premature ovarian failure (POF)</article-title><source>Autoimmun Rev</source><year>2010</year><volume>9</volume><issue>11</issue><fpage>771</fpage><lpage>774</lpage><pub-id pub-id-type="pmid">20601203</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Betterle</surname><given-names>C</given-names></name><name><surname>Rossi</surname><given-names>A</given-names></name><name><surname>Dalla Pria</surname><given-names>S</given-names></name><name><surname>Artifoni</surname><given-names>A</given-names></name><name><surname>Pedini</surname><given-names>B</given-names></name><name><surname>Gavasso</surname><given-names>S</given-names></name><etal/></person-group><article-title>Premature ovarian failure: autoimmunity and natural history</article-title><source>Clin Endocrinol</source><year>1993</year><volume>39</volume><issue>1</issue><fpage>35</fpage><lpage>43</lpage></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goswami</surname><given-names>R</given-names></name><name><surname>Marwaha</surname><given-names>RK</given-names></name><name><surname>Goswami</surname><given-names>D</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Ray</surname><given-names>D</given-names></name><name><surname>Tomar</surname><given-names>N</given-names></name><etal/></person-group><article-title>Prevalence of thyroid autoimmunity in sporadic idiopathic hypoparathyroidism in comparison to type 1 diabetes and premature ovarian failure</article-title><source>J Clin Endocrinol Metab</source><year>2006</year><volume>91</volume><issue>11</issue><fpage>4256</fpage><lpage>4259</lpage><pub-id pub-id-type="pmid">16895958</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irvine</surname><given-names>WJ</given-names></name></person-group><article-title>Premature menopause in autoimmune disease</article-title><source>Lancet</source><year>1969</year><volume>1</volume><issue>7588</issue><fpage>264</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">4178628</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallotton</surname><given-names>MB</given-names></name><name><surname>Forbes</surname><given-names>AP</given-names></name></person-group><article-title>Antibodies to cytoplasm of ova</article-title><source>Lancet</source><year>1966</year><volume>2</volume><issue>7457</issue><fpage>264</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">4161424</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gleicher</surname><given-names>N</given-names></name><name><surname>Weghofer</surname><given-names>A</given-names></name><name><surname>Oktay</surname><given-names>K</given-names></name><name><surname>Barad</surname><given-names>D</given-names></name></person-group><article-title>Do etiologies of premature ovarian aging (POA) mimic those of premature ovarian failure (POF)?</article-title><source>Hum Reprod</source><year>2009</year><volume>24</volume><issue>10</issue><fpage>2395</fpage><lpage>2400</lpage><pub-id pub-id-type="pmid">19617205</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goswami</surname><given-names>D</given-names></name><name><surname>Conway</surname><given-names>GS</given-names></name></person-group><article-title>Premature ovarian failure</article-title><source>Hum Reprod Update</source><year>2005</year><volume>11</volume><issue>4</issue><fpage>391</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">15919682</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luborsky</surname><given-names>J</given-names></name></person-group><article-title>Ovarian autoimmune disease and ovarian autoantibodies</article-title><source>J Womens Health Gend Based Med</source><year>2002</year><volume>11</volume><issue>7</issue><fpage>585</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">12396892</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>G</given-names></name><name><surname>Schoenfeld</surname><given-names>D</given-names></name><name><surname>Penney</surname><given-names>C</given-names></name><name><surname>Hurxthal</surname><given-names>K</given-names></name><name><surname>Taylor</surname><given-names>A</given-names></name><name><surname>Faustman</surname><given-names>D</given-names></name></person-group><article-title>Identification of premature ovarian failure patients with underlying autoimmunity</article-title><source>J Womens Health Gend Based Med</source><year>2000</year><volume>9</volume><issue>3</issue><fpage>275</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">10787223</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monnier-Barbarino</surname><given-names>P</given-names></name><name><surname>Forges</surname><given-names>T</given-names></name><name><surname>Faure</surname><given-names>GC</given-names></name><name><surname>B&#x000e9;n&#x000e9;</surname><given-names>MC</given-names></name></person-group><article-title>Gonadal antibodies interfering with female reproduction</article-title><source>Best Pract Res Clin Endocrinol Metab</source><year>2005</year><volume>19</volume><issue>1</issue><fpage>135</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">15826927</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coulam</surname><given-names>CB</given-names></name><name><surname>Ryan</surname><given-names>RJ</given-names></name></person-group><article-title>Prevalence of circulating antibodies directed towards ovaries among women with premature ovarian failure</article-title><source>Am J Reprod Immunol Microbiol</source><year>1985</year><volume>9</volume><issue>1</issue><fpage>23</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">3931487</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gleicher</surname><given-names>N</given-names></name><name><surname>Weghofer</surname><given-names>A</given-names></name><name><surname>Barad</surname><given-names>D</given-names></name></person-group><article-title>Female infertility due to abnormal autoimmunity: frequently overlooked and greatly underappreciated.Part II</article-title><source>Expert Rev Obstet Gynecol</source><year>2007</year><volume>2</volume><issue>4</issue><fpage>465</fpage><lpage>475</lpage></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gleicher</surname><given-names>N</given-names></name><name><surname>Weghofer</surname><given-names>A</given-names></name><name><surname>Barad</surname><given-names>D</given-names></name></person-group><article-title>Female infertility due to abnormal autoimmunity: frequently overlooked and greatly underappreciated.Part I</article-title><source>Expert Rev Obstet Gynecol</source><year>2007</year><volume>2</volume><issue>4</issue><fpage>453</fpage><lpage>464</lpage></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Betterle</surname><given-names>C</given-names></name><name><surname>Rossi</surname><given-names>A</given-names></name><name><surname>Dalla Pria</surname><given-names>S</given-names></name><name><surname>Artifoni</surname><given-names>A</given-names></name><name><surname>Pedini</surname><given-names>B</given-names></name><name><surname>Gavasso</surname><given-names>S</given-names></name><etal/></person-group><article-title>Premature ovarian failure: autoimmunity and natural history</article-title><source>Clin Endocrinol</source><year>1993</year><volume>39</volume><issue>1</issue><fpage>35</fpage><lpage>43</lpage></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wheatcroft</surname><given-names>NJ</given-names></name><name><surname>Toogood</surname><given-names>AA</given-names></name><name><surname>Li</surname><given-names>TC</given-names></name><name><surname>Cooke</surname><given-names>ID</given-names></name><name><surname>Weetman</surname><given-names>AP</given-names></name></person-group><article-title>Detection of antibodies to ovarian antigens in women with premature ovarian failure</article-title><source>Clin Exp Immunol</source><year>1994</year><volume>96</volume><issue>1</issue><fpage>122</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">8149656</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luborsky</surname><given-names>JL</given-names></name><name><surname>Visintin</surname><given-names>I</given-names></name><name><surname>Boyers</surname><given-names>S</given-names></name><name><surname>Asari</surname><given-names>T</given-names></name><name><surname>Caldwell</surname><given-names>B</given-names></name><name><surname>DeCherney</surname><given-names>A</given-names></name></person-group><article-title>Ovarian antibodies detected by immobilized antigen immunoassay in patients with premature ovarian failure</article-title><source>J Clin Endocrinol Metab</source><year>1990</year><volume>70</volume><issue>1</issue><fpage>69</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">2104631</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moncayo</surname><given-names>H</given-names></name><name><surname>Moncayo</surname><given-names>R</given-names></name><name><surname>Benz</surname><given-names>R</given-names></name><name><surname>Wolf</surname><given-names>A</given-names></name><name><surname>Lauritzen</surname><given-names>C</given-names></name></person-group><article-title>Ovarian failure and autoimmunity: detection of autoantibodies directed against both the unoccupied luteinizing hormone/human chorionic gonadotropin receptor and the hormone-receptor complex of bovine corpus luteum</article-title><source>J Clin Invest</source><year>1989</year><volume>84</volume><issue>6</issue><fpage>1857</fpage><lpage>1865</lpage><pub-id pub-id-type="pmid">2592563</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sotsion</surname><given-names>F</given-names></name><name><surname>Bottazzo</surname><given-names>GF</given-names></name><name><surname>Doniach</surname><given-names>D</given-names></name></person-group><article-title>Immunoofluorescence studies on antibodies to steroid-producing cells, and to germline cells in endocrine disease and infertility</article-title><source>Clin Exp Immunol</source><year>1980</year><volume>39</volume><issue>1</issue><fpage>97</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">6771073</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horejsi</surname><given-names>J</given-names></name><name><surname>Martinek</surname><given-names>J</given-names></name><name><surname>Novakova</surname><given-names>D</given-names></name><name><surname>Madar</surname><given-names>J</given-names></name><name><surname>Brandejska</surname><given-names>M</given-names></name></person-group><article-title>Autoimmune antiovarian antibodies and their impact on the success of an IVF/ET program</article-title><source>Ann N Y Acad Sci</source><year>2000</year><volume>900</volume><fpage>351</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">10818424</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>WR</given-names></name><name><surname>Lavy</surname><given-names>G</given-names></name><name><surname>DeCherney</surname><given-names>AH</given-names></name><name><surname>Visintin</surname><given-names>I</given-names></name><name><surname>Economy</surname><given-names>K</given-names></name><name><surname>Luborsky</surname><given-names>JL</given-names></name></person-group><article-title>Evidence of gonadal and gonadotropin antibodies in woman with suboptimal ovarian response to exogenous gonadotropin</article-title><source>Obstet Gynecol</source><year>1990</year><volume>75</volume><issue>5</issue><fpage>795</fpage><lpage>799</lpage><pub-id pub-id-type="pmid">2109293</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luborsky</surname><given-names>J</given-names></name><name><surname>Pong</surname><given-names>R</given-names></name></person-group><article-title>Pregnancy outcome and ovarian antibodies in infertility patients undergoing controlled ovarian hyperstimulation</article-title><source>Am J Reprod Immunol</source><year>2000</year><volume>44</volume><issue>5</issue><fpage>261</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">11125786</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luborsky</surname><given-names>JL</given-names></name><name><surname>Thiruppathi</surname><given-names>P</given-names></name><name><surname>Rivany</surname><given-names>B</given-names></name><name><surname>Roussev</surname><given-names>R</given-names></name><name><surname>Coulam</surname><given-names>C</given-names></name><name><surname>Radwanska</surname><given-names>E</given-names></name></person-group><article-title>Evidence for different etiologies of low estradiol response to FSH: age-related accelerated luteinization of follicles of presence of ovarian autoantibodies</article-title><source>Hum Reprod</source><year>2002</year><volume>17</volume><issue>10</issue><fpage>2641</fpage><lpage>2649</lpage><pub-id pub-id-type="pmid">12351542</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mignot</surname><given-names>MH</given-names></name><name><surname>Drexhage</surname><given-names>HA</given-names></name><name><surname>Kleingeld</surname><given-names>M</given-names></name><name><surname>Van de Plass che Boers</surname><given-names>EM</given-names></name><name><surname>Rao</surname><given-names>BR</given-names></name><name><surname>Schoemaker</surname><given-names>J</given-names></name></person-group><article-title>Premature ovarian failure.II: Considerations of cellular immunity defects</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>1989</year><volume>30</volume><issue>1</issue><fpage>67</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">2647539</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyake</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Takeuchi</surname><given-names>S</given-names></name></person-group><article-title>Implications of circulating autoantibodies and peripheral blood lymphocyte subset for the genesis of premature ovarian failure</article-title><source>J Reprod Immunol</source><year>1987</year><volume>12</volume><issue>3</issue><fpage>163</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">3123670</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakaguchi</surname><given-names>S</given-names></name><name><surname>Sakaguchi</surname><given-names>N</given-names></name><name><surname>Asano</surname><given-names>M</given-names></name><name><surname>Itoh</surname><given-names>M</given-names></name><name><surname>Toda</surname><given-names>M</given-names></name></person-group><article-title>Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25).Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases</article-title><source>J Immunol</source><year>1995</year><volume>155</volume><issue>3</issue><fpage>1151</fpage><lpage>1164</lpage><pub-id pub-id-type="pmid">7636184</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>SA</given-names></name><name><surname>Buckner</surname><given-names>JH</given-names></name></person-group><article-title>CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game</article-title><source>J Immunol</source><year>2011</year><volume>187</volume><issue>5</issue><fpage>2061</fpage><lpage>2066</lpage><pub-id pub-id-type="pmid">21856944</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chernysmov</surname><given-names>VP</given-names></name><name><surname>Radysh</surname><given-names>TV</given-names></name><name><surname>Gura</surname><given-names>IV</given-names></name><name><surname>Tatarchuk</surname><given-names>TP</given-names></name><name><surname>Khominskaya</surname><given-names>ZB</given-names></name></person-group><article-title>Immune disorders in women with premature ovarian failure in initial period</article-title><source>Am J Reprod Immunol</source><year>2001</year><volume>46</volume><issue>3</issue><fpage>220</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">11554695</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>PC</given-names></name><name><surname>Tang</surname><given-names>GW</given-names></name><name><surname>Lawton</surname><given-names>JW</given-names></name></person-group><article-title>Lymphocyte subsets and serum immunoglobulins in patients with premature ovarian failure before and after estrogen replacement</article-title><source>Hum Reprod</source><year>1993</year><volume>8</volume><issue>5</issue><fpage>714</fpage><lpage>716</lpage><pub-id pub-id-type="pmid">8314965</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Houten</surname><given-names>EL</given-names></name><name><surname>Themmen</surname><given-names>AP</given-names></name><name><surname>Visser</surname><given-names>JA</given-names></name></person-group><article-title>Anti-M&#x000fc;llerian hormone (AMH): regulator and marker of ovarian function</article-title><source>Ann Endocrinol (Paris)</source><year>2010</year><volume>71</volume><issue>3</issue><fpage>191</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">20362961</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baird</surname><given-names>DD</given-names></name><name><surname>Steiner</surname><given-names>AZ</given-names></name></person-group><article-title>Anti-M&#x000fc;llerian hormone: a potential new tool in epidemiologic studies of female fecundability</article-title><source>Am J Epidemiol</source><year>2012</year><volume>175</volume><issue>4</issue><fpage>245</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">22247047</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Rooij</surname><given-names>IA</given-names></name><name><surname>Broekmans</surname><given-names>FJ</given-names></name><name><surname>Scheffer</surname><given-names>GJ</given-names></name><name><surname>Looman</surname><given-names>CW</given-names></name><name><surname>Habbema</surname><given-names>JD</given-names></name><name><surname>de Jong</surname><given-names>FH</given-names></name><etal/></person-group><article-title>Serum anti m&#x000fc;llerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study</article-title><source>Fertil Steril</source><year>2005</year><volume>83</volume><issue>4</issue><fpage>979</fpage><lpage>987</lpage><pub-id pub-id-type="pmid">15820810</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domingues</surname><given-names>TS</given-names></name><name><surname>Rocha</surname><given-names>AM</given-names></name><name><surname>Serafini</surname><given-names>PC</given-names></name></person-group><article-title>Tests for ovarian reserve: reliability and utility</article-title><source>Curr Opin Obstet Gynecol</source><year>2010</year><volume>22</volume><issue>4</issue><fpage>271</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">20543692</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meden-Vrtovec</surname><given-names>H</given-names></name><name><surname>Osredkar</surname><given-names>J</given-names></name></person-group><article-title>Anti-M&#x000fc;llerian hormone- a predictor of ovarian reserve</article-title><source>Zdrav Vestn</source><year>2010</year><volume>79</volume><issue>6</issue><fpage>507</fpage><lpage>511</lpage></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>SM</given-names></name><name><surname>Anderson</surname><given-names>RA</given-names></name><name><surname>Broekmans</surname><given-names>FJ</given-names></name><name><surname>Raine-Fenning</surname><given-names>N</given-names></name><name><surname>Fleming</surname><given-names>R</given-names></name><name><surname>La Marca</surname><given-names>A</given-names></name></person-group><article-title>Anti-M&#x000fc;llerian hormone: clairvoyance or crystal clear?</article-title><source>Hum Reprod</source><year>2012</year><volume>27</volume><issue>3</issue><fpage>631</fpage><lpage>636</lpage><pub-id pub-id-type="pmid">22238112</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knauff</surname><given-names>EA</given-names></name><name><surname>Eijkemans</surname><given-names>MJ</given-names></name><name><surname>Lambalk</surname><given-names>CB</given-names></name><name><surname>ten Kate- Booij</surname><given-names>MJ</given-names></name><name><surname>Hoek</surname><given-names>A</given-names></name><name><surname>Beerendonk</surname><given-names>CC</given-names></name><etal/></person-group><article-title>Anti-M&#x000fc;llerian hormone, inhibin B, and antral follicle count in young women with ovarian failure</article-title><source>J Clin Endocrinol Metab</source><year>2009</year><volume>94</volume><issue>3</issue><fpage>786</fpage><lpage>792</lpage><pub-id pub-id-type="pmid">19066296</pub-id></element-citation></ref></ref-list></back></article>